Your session is about to expire
← Back to Search
Virus Therapy
agenT-797 for Respiratory Distress Syndrome
Phase 1 & 2
Waitlist Available
Research Sponsored by MiNK Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through day 30 (every 12 hours, as feasible)
Awards & highlights
Summary
This trial tests agenT-797, a cell therapy using special immune cells, in patients with severe lung issues from COVID-19 or influenza. The therapy aims to boost the immune system to reduce inflammation and fight infection.
Eligible Conditions
- Respiratory Distress Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline through day 30 (every 12 hours, as feasible)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through day 30 (every 12 hours, as feasible)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Change From Baseline In C-reactive Protein
Number Of Participants Experiencing Viral Reactivation And Fungal Infections
Trial Design
1Treatment groups
Experimental Treatment
Group I: Dosage and CohortsExperimental Treatment1 Intervention
Cohort 1: 100 × 10\^6 iNKT cells; Cohort 2: 300 × 10\^6 iNKT cells; Cohorts 3 to 4: 1000 × 10\^6 iNKT cells
Dosage Frequency and Mode of Administration: agenT-797 will be administered to hospitalized participants as a single intravenous infusion.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
agenT-797
2022
Completed Phase 2
~70
Find a Location
Who is running the clinical trial?
MiNK TherapeuticsLead Sponsor
2 Previous Clinical Trials
47 Total Patients Enrolled
Medical DirectorStudy DirectorMiNK Therapeutics
2,834 Previous Clinical Trials
8,079,760 Total Patients Enrolled
1 Trials studying Respiratory Distress Syndrome
40 Patients Enrolled for Respiratory Distress Syndrome
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a serious heart condition called cardiomyopathy.You have a respiratory disease like chronic obstructive pulmonary disease (COPD) that is severe and requires oxygen therapy at home, frequent hospitalizations, or use of strong steroids in the past year.You are currently involved in a different clinical trial using an experimental treatment that is not approved for any other use.You have received vaccines with live viruses in the past month before starting the study treatment.You are allergic to the cell therapy treatment or the solution used to preserve it.
Research Study Groups:
This trial has the following groups:- Group 1: Dosage and Cohorts
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger